Korea IND Filing Moves Alteogen's Eylea Biosimilar Forward

 
• By Jung Won Shin

South Korean biotech Alteogen is progressing the development of its Eylea biosimilar both at home and abroad, with the hope of becoming a global first mover with its version in wet AMD, backed by formulation and manufacturing patents.

Eye
Alteogen Files Korea IND For Eylea Biosimilar • Source: Shutterstock

More from South Korea

More from Focus On Asia